Free Trial
→ Three oil giants buried the same discovery for 50 years (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.95
+6.0%		$70.27
$60.22
▼
$93.42
$13.83B0.972.65 million shs5.77 million shs
Evotec SE stock logo
EVTCY
Evotec
$1.53
-3.2%		$1.66
$14.22
▼
$26.57
$505.24M0.982,407 shs73,252 shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
▼
$64.41
$4.12B0.772.76 million shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+5.97%+9.32%+13.91%-6.42%+12.50%
Evotec SE stock logo
EVTCY
Evotec
-1.56%+2.60%-3.66%-17.28%-61.74%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.95
+6.0%		$70.27
$60.22
▼
$93.42
$13.83B0.972.65 million shs5.77 million shs
Evotec SE stock logo
EVTCY
Evotec
$1.53
-3.2%		$1.66
$14.22
▼
$26.57
$505.24M0.982,407 shs73,252 shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
▼
$64.41
$4.12B0.772.76 million shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+5.97%+9.32%+13.91%-6.42%+12.50%
Evotec SE stock logo
EVTCY
Evotec
-1.56%+2.60%-3.66%-17.28%-61.74%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.82
Moderate Buy$104.1638.97% Upside
Evotec SE stock logo
EVTCY
Evotec
0.00
N/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EVTCY, MRTX, and BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/30/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/30/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$110.00 ➝ $100.00
10/30/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$87.00 ➝ $88.00
10/21/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$97.00 ➝ $87.00
10/19/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$115.00 ➝ $120.00
10/19/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetNeutral$94.00 ➝ $91.00
10/15/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$82.00 ➝ $92.00
10/14/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
10/7/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$157.00 ➝ $156.00
10/6/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M29.18N/AN/A($10.77) per share-6.96
Evotec SE stock logo
EVTCY
Evotec
$572.16M0.91$0.01 per share105.53$2.52 per share0.63
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$12.44M331.01N/AN/A$17.31 per share3.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.04N/AN/AN/A-59.84%N/A-48.17%N/A
Evotec SE stock logo
EVTCY
Evotec
$7.14M$0.413.85N/AN/A20.85%16.02%7.81%N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/A

Latest EVTCY, MRTX, and BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5423-$0.42+$0.1223-$0.42$293.47 million$353.17 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Evotec SE stock logo
EVTCY
Evotec
0.53
2.57
2.50
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
7.54
7.40

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Evotec SE stock logo
EVTCY
Evotec
N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Evotec SE stock logo
EVTCY
Evotec
N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
3.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Evotec SE stock logo
EVTCY
Evotec
4,200330.22 millionN/ANot Optionable
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
58770.15 million67.86 millionNo Data

Recent News About These Companies

BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia
October 31, 2025  |  fiercebiotech.comF
Mirati's Flagship Drug Faces Mounting Pressure from Lilly's New Therapy
September 4, 2025  |  aktiencheck.deA
Mirati Therapeutics Stock Price History
May 26, 2025  |  investing.comhttps://www.investing.com/equities/mirati-ther-historical-data
New GTPase KRAS mutant inhibitors disclosed in Mirati patent
December 12, 2024  |  bioworld.comB
Mirati Therapeutics Receives Untitled Letter from OPDP for Overstating Cancer Drug Efficacy
October 15, 2024  |  policymed.comP
Pharma M&A rumour mill grinds out Mirati's name again
August 16, 2024  |  pharmaphorum.comP
Mirati's Charles Baum takes the helm at Terremoto Biosciences
July 25, 2024  |  fiercebiotech.comF
Bristol Myers Squibb concludes acquisition of Mirati Therapeutics
January 26, 2024  |  medicaldialogues.inM
Bristol Myers Squibb completes acquisition of Mirati Therapeutics
January 25, 2024  |  pharmabiz.comP
Mirati Therapeutics Receives Marketing Authorization For KRAZATI From European Commission
January 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/mirati-therapeutics-receives-marketing-authorization-for-krazati-from-european-commission-1032957219
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
January 10, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/european-commission-approves-krazati-adagrasib-130000810.html?.tsrc=rss
Mirati Therapeutics Inc [MRTX] Stock sold by Insider Christensen Jamie for $0.14 million
January 2, 2024  |  knoxdaily.comK
Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition
December 25, 2023  |  seekingalpha.comhttps://seekingalpha.com/article/4659531-evaluating-mirati-therapeutics-cvr-value-in-the-wake-of-the-bristol-myers-acquisition
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln
December 22, 2023  |  reuters.comhttps://www.reuters.com/markets/deals/bristol-myers-buy-karuna-therapeutics-14-billion-wsj-2023-12-22/?ref=upstract.com
Karuna Therapeutics soars after $14 billion takeover by Bristol Myers
December 22, 2023  |  msn.comhttps://www.msn.com/en-us/health/other/karuna-therapeutics-soars-after-14-billion-takeover-by-bristol-myers/ar-AA1lU4Mu
Citigroup Downgrades Mirati Therapeutics (MRTX)
December 20, 2023  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/citigroup-downgrades-mirati-therapeutics-mrtx/ar-AA1lOVlw
Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 Shares
December 20, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/mirati-therapeutics-inc-evp-chief-160123567.html?.tsrc=rss
Mirati Therapeutics: Submission Of Matters To A Vote Of Securities Holders
December 15, 2023  |  cbonds.comC
Insider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)
December 15, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/insider-sell-alert-evp-benjamin-120549966.html?.tsrc=rss
Mirati Therapeutics Inc MRTX
December 12, 2023  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$74.95 +4.22 (+5.97%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$74.65 -0.30 (-0.40%)
As of 10/30/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Evotec stock logo

Evotec OTCMKTS:EVTCY

$1.53 -0.05 (-3.16%)
As of 10/30/2026

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Mirati Therapeutics stock logo

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas